Antares Pharma Inc. (ATRS)

3.21
0.10 3.10
NASDAQ : Health Technology
Prev Close 3.11
Open 3.12
Day Low/High 3.11 / 3.22
52 Wk Low/High 1.99 / 3.93
Volume 295.37K
Avg Volume 837.10K
Exchange NASDAQ
Shares Outstanding 157.54M
Market Cap 496.25M
EPS -0.10
P/E Ratio N/A
Div & Yield N.A. (N.A)
Antares Pharma To Host Fourth Quarter 2014 Operating And Financial Results Conference Call

Antares Pharma To Host Fourth Quarter 2014 Operating And Financial Results Conference Call

Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its fourth quarter 2014 financial results before the market opens on Thursday, March 12, 2015, and host a conference call shortly thereafter at 8:30 a.

Antares Pharma Announces Positive Top-Line Pharmacokinetic Results From The QuickShot® Phase 3 Study In Testosterone Deficient Men

Antares Pharma Announces Positive Top-Line Pharmacokinetic Results From The QuickShot® Phase 3 Study In Testosterone Deficient Men

Antares Pharma, Inc. (NASDAQ: ATRS) today announced positive top-line pharmacokinetic results that showed that the primary endpoint was achieved in the Company's ongoing, multi-center, phase 3 clinical study (QST-13-003)...

Antares Pharma To Present At The Cowen And Company 35Th Annual Healthcare Conference

Antares Pharma To Present At The Cowen And Company 35Th Annual Healthcare Conference

Antares Pharma, Inc. (NASDAQ:ATRS) today announced that Eamonn P.

Antares Pharma To Present At The 2015 RBC Capital Markets' Global Healthcare Conference

Antares Pharma To Present At The 2015 RBC Capital Markets' Global Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Eamonn P.

ATRS: Insiders vs. Shorts

ATRS: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 01/15/2015 settlement date, and Antares Pharma Inc. is one of the most shorted stocks of the Russell 3000, based on 8.45 "days to cover" versus the median component at 5.09.

First Week of ATRS March 20th Options Trading

First Week of ATRS March 20th Options Trading

Investors in Antares Pharma Inc. saw new options begin trading this week, for the March 20th expiration.

Antares Pharma Provides Regulatory Update On Sumatriptan Injection USP

Antares Pharma Provides Regulatory Update On Sumatriptan Injection USP

Antares Pharma, Inc. (NASDAQ:ATRS) today announced that the U.

Antares Pharma Announces Update To QuickShot® Testosterone Program

Antares Pharma Announces Update To QuickShot® Testosterone Program

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that it has received written recommendations from the U.

Antares Pharma To Present At The 33rd Annual J.P. Morgan Healthcare Conference

Antares Pharma To Present At The 33rd Annual J.P. Morgan Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Eamonn P.

Interesting ATRS Put Options For August 2015

Interesting ATRS Put Options For August 2015

Investors in Antares Pharma Inc. saw new options become available this week, for the August 2015 expiration.

Short Interest In Antares Pharma Decreases By 11%

Short Interest In Antares Pharma Decreases By 11%

The most recent short interest data has been released by the NASDAQ for the 11/28/2014 settlement date, which shows a 1,559,189 share decrease in total short interest for Antares Pharma Inc. , to 12,464,088, a decrease of 11.12% since 11/14/2014.

Antares Pharma To Present At The 25th Annual Oppenheimer Healthcare Conference

Antares Pharma To Present At The 25th Annual Oppenheimer Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Eamonn P.

Antares Pharma To Present At The 26th Annual Piper Jaffray Healthcare Conference

Antares Pharma To Present At The 26th Annual Piper Jaffray Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Eamonn P.

Antares Pharma Appoints James E. Fickenscher, Senior Vice President, Chief Financial Officer

Antares Pharma Appoints James E. Fickenscher, Senior Vice President, Chief Financial Officer

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of James E.

Antares Pharma Reports Third Quarter 2014 Operating And Financial Results

Antares Pharma Reports Third Quarter 2014 Operating And Financial Results

Antares Pharma, Inc. (NASDAQ: ATRS) today reported operating and financial results for the third quarter ended September 30, 2014.

Antares Pharma Announces Last Patient Enrolled In Phase 3 QuickShot® Study Evaluating Testosterone-Deficient Adult Males

Antares Pharma Announces Last Patient Enrolled In Phase 3 QuickShot® Study Evaluating Testosterone-Deficient Adult Males

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that the last patient has been enrolled in a double-blind, multiple-dose, phase 3 study to evaluate the efficacy and safety of QuickShot ® Testosterone (QS T)...

Antares Pharma To Host Third Quarter 2014 Operating And Financial Results Conference Call

Antares Pharma To Host Third Quarter 2014 Operating And Financial Results Conference Call

Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its third quarter 2014 financial results before the market opens on Thursday, November 6, 2014 and host a conference call at 8:30 a.

Interesting ATRS Call Options For May 2015

Interesting ATRS Call Options For May 2015

Investors in Antares Pharma Inc. saw new options become available this week, for the May 2015 expiration.

Antares Pharma Announces Promotion Of Robert F. Apple To Chief Operating Officer

Antares Pharma Announces Promotion Of Robert F. Apple To Chief Operating Officer

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Robert F.

Antares Pharma To Participate At The Morgan Stanley Healthcare Conference

Antares Pharma To Participate At The Morgan Stanley Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Eamonn P.

5 Breakout Stocks Under $10 Set to Soar

5 Breakout Stocks Under $10 Set to Soar

These under-$10 stocks look ready to break out and trade higher from current levels.

ATRS: Insiders vs. Shorts

ATRS: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 07/31/2014 settlement date, and Antares Pharma Inc. is one of the most shorted stocks of the Russell 3000, based on 9.03 "days to cover" versus the median component at 6.30.

Antares Pharma Reports Second Quarter 2014 Operating And Financial Results

Antares Pharma Reports Second Quarter 2014 Operating And Financial Results

Antares Pharma, Inc. (NASDAQ: ATRS) today reported operating and financial results for the second quarter ended June 30, 2014.

Antares Pharma To Host Second Quarter 2014 Operating And Financial Results Conference Call

Antares Pharma To Host Second Quarter 2014 Operating And Financial Results Conference Call

Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its second quarter 2014 financial results before the market opens on Thursday, August 7, 2014, and host a conference call shortly thereafter at 8:30 a.

Antares Pharma Announces First Patient Dosed In Phase 3 QuickShot Study Evaluating Testosterone-Deficient Adult Males

Antares Pharma Announces First Patient Dosed In Phase 3 QuickShot Study Evaluating Testosterone-Deficient Adult Males

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that the first patient has been dosed in a double-blind, multiple-dose, phase 3 study to evaluate the efficacy and safety of QuickShot ® Testosterone (QS T)...

Interesting ATRS Put Options For February 2015

Interesting ATRS Put Options For February 2015

Investors in Antares Pharma Inc. saw new options begin trading this week, for the February 2015 expiration.

Rapid Restoration And Consistent Maintenance Of Steady Blood Levels Achieved With Once-Weekly Subcutaneous Administration Of Testosterone Delivered With A Novel Auto Injector

Rapid Restoration And Consistent Maintenance Of Steady Blood Levels Achieved With Once-Weekly Subcutaneous Administration Of Testosterone Delivered With A Novel Auto Injector

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the presentation of a scientific poster at the 16 th International Congress of Endocrinology and the Endocrine Society’s 96 th Annual Meeting & Expo held in...

Antares Pharma Announces Changes In Senior Leadership

Antares Pharma Announces Changes In Senior Leadership

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the resignation of Paul K.

Antares Pharma To Present At The Jefferies 2014 Global Healthcare Conference

Antares Pharma To Present At The Jefferies 2014 Global Healthcare Conference

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that Paul K.

Antares Pharma Appoints Jennifer Evans Stacey, Esq., Senior Vice President, General Counsel, Human Resources And Secretary

Antares Pharma Appoints Jennifer Evans Stacey, Esq., Senior Vice President, General Counsel, Human Resources And Secretary

Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Jennifer Evans Stacey, Esq.

TheStreet Quant Rating: D (Sell)